COVIVIO |
Market Closed -
Other stock markets
|
After market 09:49:06 pm | |||
| 47.02 EUR | -0.70% |
|
46.85 | -0.36% |
| 24/04 | COVIVIO : Invest Securities remains Buy after sales release | CF |
| 24/04 | Covivio: stable revenues in Q1 | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 82% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- This company will be of major interest to investors in search of a high dividend stock.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.77 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Commercial REITs
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.51% | 5.08B | - | ||
| -5.95% | 46.77B | A- | ||
| -7.27% | 20.84B | A- | ||
| -4.33% | 13.18B | A- | ||
| +17.27% | 11.68B | A | ||
| -4.85% | 9.7B | B+ | ||
| +1.12% | 8.57B | A- | ||
| -14.19% | 8.4B | B- | ||
| +2.35% | 7.69B | A- | ||
| -18.65% | 5.58B | A |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- COV Stock
- 0J6V Stock
- Ratings Covivio
